Fate Therapeutics Stock Today
| FATE Stock | USD 3.17 0.49 18.28% |
Performance0 of 100
| Odds Of DistressOver 56
|
Fate Therapeutics is trading at 3.17 as of the 30th of November 2024, a 18.28 percent increase since the beginning of the trading day. The stock's lowest day price was 3.07. Fate Therapeutics has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Fate Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of October 2013 | Category Healthcare | Classification Health Care |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. The company has 113.89 M outstanding shares of which 10.39 M shares are currently shorted by private and institutional investors with about 7.2 trading days to cover. More on Fate Therapeutics
Moving against Fate Stock
Fate Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Scott Wolchko | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsFate Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Fate Therapeutics' financial leverage. It provides some insight into what part of Fate Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fate Therapeutics (FATE) is traded on NASDAQ Exchange in USA. It is located in 12278 Scripps Summit Drive, San Diego, CA, United States, 92131 and employs 181 people. Fate Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 361.04 M. Fate Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 113.89 M outstanding shares of which 10.39 M shares are currently shorted by private and institutional investors with about 7.2 trading days to cover.
Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Fate Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Fate Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fate Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fate Therapeutics. Please pay attention to any change in the institutional holdings of Fate Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Fate Ownership Details
Fate Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-09-30 | 3.4 M | |
| Baker Bros Advisors Lp | 2024-09-30 | 3 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | |
| Assenagon Asset Management Sa | 2024-09-30 | 2.4 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 2.3 M | |
| Geode Capital Management, Llc | 2024-09-30 | 2.3 M | |
| Vestal Point Capital Lp | 2024-06-30 | 2 M | |
| Bank Of America Corp | 2024-06-30 | 2 M | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.6 M | |
| Redmile Group, Llc | 2024-09-30 | 13.2 M | |
| Vanguard Group Inc | 2024-09-30 | 10.4 M |
Fate Therapeutics Historical Income Statement
Fate Stock Against Markets
Fate Therapeutics Corporate Management
| Barbara Hickingbottom | Senior Development | Profile | |
| Andrew Henry | Senior Operations | Profile | |
| YuWaye MD | Chief Officer | Profile | |
| Cindy Tahl | General Secretary | Profile | |
| Edward III | Chief Officer | Profile | |
| Bahram Valamehr | Chief Development Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.123 | Quarterly Revenue Growth 0.581 | Return On Assets (0.22) | Return On Equity (0.47) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.